Name | Target | Route | Trial phase | Inclusion criteria (prior treatments; subject age; spleen size) | Subjects Baseline Characteristics | Study duration (current /planned) | Accrual (current accrual #/target accrual #) | Efficacy | Adverse Events | Clinicaltrials.gov Registration | References |
---|---|---|---|---|---|---|---|---|---|---|---|
MMB | JAK1/2/ACVR1 | PO | III | One prior JAKi for ≥ 90 days; ≥ 18 years; palpable spleen ≥ 5 cm | N/A | 27/96 months | 195/195 | TI-R (31%); SVR (100%) at W24 | Thrombocytopenia Anemia Infection Peripheral neuropathy | NCT04173494 | [3] |
Pacritinib | JAK2/ACVR1 | PO | III | JAKi-naïve patients; ≥ 18 years; palpable spleen ≥ 5 cm | All patients had platelet counts ≤ 100 × 109/L | 40/40 months | 327/327 | TL-R (24% on SIMPLIFY criteria, 37% on Gale criteria) at W24 | Not reported | NCT01773187 | [4] |
TP-3654 | PIM1 | PO | I/II | At least one prior JAKi; ≥ 18 years; palpable spleen ≥ 5 cm or SV ≥ 450 cm3 | Median age of 70 years; median spleen volume of 2370 cm3 | 32/55 months | 8/60 | SVR (83%); TSS50 (66%); at W12 | Nausea Vomiting Diarrhea | NCT04176198 | [5] |
IMG-7289 | LSD1 | PO | II | Prior JAKi or JAKi-naïve patients; ≥ 18 years; | Median age of 68 years; median spleen volume of 1354 cm3 | 56/56 months | 89/89 | SVR (66%); TSS50 (19%); TI-R (90%); BMF (53%) at W24 | Dysgeusia Diarrhea | NCT03136185 | [6] |